User profiles for Jon Packham
Jon PackhamAssociate Professor of Rheumatology, University of Nottingham Verified email at mpft.nhs.uk Cited by 6999 |
[HTML][HTML] Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
Background Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a
recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (…
recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (…
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a …
Background The safety and immunogenicity profile of COVID-19 vaccines when administered
concomitantly with seasonal influenza vaccines have not yet been reported. We therefore …
concomitantly with seasonal influenza vaccines have not yet been reported. We therefore …
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis
…, A Kowalczyk, H Taylor, F Ibrahim, JC Packham… - …, 2012 - academic.oup.com
Objective. MTX is widely used to treat synovitis in PsA without supporting trial evidence. The
aim of our study was to test the value of MTX in the first large randomized placebo-…
aim of our study was to test the value of MTX in the first large randomized placebo-…
Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic
…, A Brownfield, DL Mattey, JC Packham - …, 2009 - academic.oup.com
Objectives. Depression is common in RA and may be influenced by both disease activity
and severity. The aims of this study were to investigate the prevalence of depression in RA …
and severity. The aims of this study were to investigate the prevalence of depression in RA …
Case identification of depression in patients with chronic physical health problems: a diagnostic accuracy meta-analysis of 113 studies
Background Depression is more likely in patients with chronic physical illness, and is
associated with increased rates of disability and mortality. Effective treatment of depression may …
associated with increased rates of disability and mortality. Effective treatment of depression may …
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled …
…, A Walker, R Munro, J McLaren, E McRorie, J Packham… - The Lancet, 2016 - thelancet.com
Background Tumour necrosis factor (TNF) inhibition and B-cell depletion are highly effective
treatments for active rheumatoid arthritis, but so far no randomised controlled trials have …
treatments for active rheumatoid arthritis, but so far no randomised controlled trials have …
[HTML][HTML] Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis
…, GM Alenius, E Giardina, J Packham… - Nature …, 2015 - nature.com
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis and,
despite the larger estimated heritability for PsA, the majority of genetic susceptibility loci …
despite the larger estimated heritability for PsA, the majority of genetic susceptibility loci …
[HTML][HTML] Diagnostic delay in axial spondyloarthritis: a systematic review
Identification of axial spondyloarthritis (axSpA) remains challenging, frequently resulting in
a diagnostic delay for patients. Current benchmarks of delay are usually reported as mean …
a diagnostic delay for patients. Current benchmarks of delay are usually reported as mean …
Genome-wide DNA methylation profiling in rheumatoid arthritis identifies disease-associated methylation changes that are distinct to individual T-and B-lymphocyte …
…, KE Haworth, JC Packham, JC Packham… - Epigenetics, 2014 - Taylor & Francis
Full article: Genome-wide DNA methylation profiling in rheumatoid arthritis identifies disease-associated
methylation changes that are distinct to individual T- and B-lymphocyte …
methylation changes that are distinct to individual T- and B-lymphocyte …
Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial
Background The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7%
efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-…
efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-…